Kornimate/medical-research-clean huggingface dataset:
clinical characteristics and outcomes of 187 critically ill patients with coronavirus disease 2019 (covid-19)

Conditions: COVID-19

Summary: this case series describes the clinical characteristics, treatment and outcomes of patients with laboratory confirmed covid-19 admitted to a 35 beds intensive care unit of a tertiary hospital in northeast brazil.

this retrospective observational study will be carried out at hospital são domingos, state of maranhao, brasil. it is a tertiary hospital with 450 beds and six intensive care units (icu) with a total of 63 beds. with the admission of the first patients with coronavirus disease 2019 (covid-19) as of march 20, we initially made available a 12 beds icu exclusively for the treatment of patients with covid-19. at the beginning of april, the number of beds was increased to 35 and, immediately afterwards, two semi-intensive units (16 and 21 beds) were created for patients in need of non-invasive respiratory support, with the 35 beds icu 35 dedicated to receive only patients in need of high-level support (usually invasive mechanical ventilation) with or without other organ dysfunctions. in the period from march 20 to june 15, 2020, 935 patients with confirmed diagnosis (rt-pcr) of covid-19 were admitted to the hospital and 187 of them were treated in the icu. data were obtained from the hospital's electronic medical record. demographic and severity data included age, sex, simplified acute physiology 3 (saps 3) and sequential organ failure assessment (sofa) scores at admission, nutritional risk determined by nutritional risk screening 2002 (nrs-2002) and commodities. clinical and laboratory data on arrival at the icu including partial pressure of oxygen in arterial bood / inspired fraction of oxygen (pao2 / fio2) complete blood count and pcr d-dimer, ferritin, fibrinogen and lactic acid dehydrogenasew (ldh). drug interventions including use of hydroxychloroquine, corticosteroids, heparin, tocilizumab. characteristics of invasive and non-invasive respiratory support, use of prone position, ecmo and vasoactive drugs. the main complications, acute kidney injury requiring hemodialysis, secondary infectious complications will be documented as well as the outcomes.

Eligibility criteria:
inclusion criteria: * all patients admitted to the 35 beds icu between march 20 and june 15, 2020 with laboratory confirmed diagnosis of covid-19 (rt-pcr). exclusion criteria: * patients admitted to the icu in which the rt-pcr was negative, and patients that did not require high level life support (rrt, prone position, ecmo, hemodymnamic monitoring and support).

Keywords: covid-19 critically ill patients outcomes treatment
lamellar body counts on gastric aspirate in healthy term newborns

Conditions: Infant, Newborn, Diseases

Summary: the aim of this study to determine the reference ranges of lbc on gastric aspirate in healthy term newborns.

lamellar bodies represent the storage form of lung surfactant. surfactant is produced in alveolar type ii cells and transported to the alveolar surface as lamellar bodies. lamellar bodies are present in the amniotic fluid and also gastric aspirate.it has become a preferred test for determine fetal lung maturity, because of the rapid, inexpensive, easily accessible and easily applicable method.

Eligibility criteria:
inclusion criteria: * infants born at ≥ 37 weeks of gestation and birth weight ≥ 2500 g exclusion criteria: * intubated immediately after birth, infants with respiratory distress, infants with gestational pathology that can influence fetal lung maturity (cases with premature rupture of membranes, preeclampsia/eclampsia, gestational diabetes, oligohydramnios/polyhidramnios or antenatal steroid use), infants with major congenital or chromosomal abnormalities and lack of parental consent, therapeutic infusion was given in the amniotic cavity or if gastric aspirate contaminated by meconium, pus or blood.
exploring the possibility to use glycosyltransferase as a prognosis marker of neuroblastoma

Conditions: Neuroblastoma

Summary: well-regulated glycosylation is essential for the normal development of the nervous system. altered expression of glycosyltransferases with resulting dysregulated glycosylation of neuroblastic cells might lead to the development of nb. the β1,4-n-acetylgalactosaminyltransferase iii (b4galnt3) exhibits galnac transferase activity to form the galnacβ1,4glcnac (lacdinac or ldn) structure. the drosophila b4galnta, homolog of human b4galnt3, has been suggested to regulate the neuronal development. by immunohistochemical studies, we demonstrated that the expression of b4galnt3 correlated well with histological grade of differentiation in nb tumor samples. since well differentiated tumors usually carry a better prognosis, we thus speculate that expression of b4galnt3 in tumor tissues can a favorable prognostic factor of nb. to explore the role of b4galnt3 in the prognosis of nb, we propose the following project with two specific aims: aim ⅰ: establishing the significance of b4galnt3 in the prognosis of nb: we plan to collect 90 nb tumor samples, and evaluate the rna and protein expression levels by q-pcr, western blot, and immunohistochemistry in the tumor samples. the results will be compared with the other clinicopathological and biological factors of nb. also the expression levels of b4galnt3 in tumor tissues will be correlated to the patients' outcome to clarify whether b4galnt3 could be a prognosis marker of nb. aim ii: clarifying the effects of b4galnt3 on nb cell behavior in vitro and in vivo. for further strengthening the prognostic role of b4galnt3 in nb, nb cell phenotype and behavior changes after overexpression or knock-down of b4galnt3 are evaluated by in vitro assays as well as by a nude mice xenograft model. in summary, if our project can establish the role of b4galnt3 expression in nb, we may further subclassify the nb patients, and give the nb patients more appropriate therapies to improve patients' outcome. furthermore, b4galnt3 could potentially serves as a therapeutic target in the future.


Eligibility criteria:
inclusion criteria: * neuroblastoma patients with complete follow-up and sufficient samples for study exclusion criteria: * neuroblastoma patients without complete follow-up or sufficient samples for study

Keywords: neuroblastoma b4galnt3 prognosis
the effect on caregivers of a family support program

Conditions: Caregiver Burnout

Summary: the purpose of this study is to investigate the effect of a family support program based on the nurse-led case management model on individuals providing care for patients who are confined to bed at home.

it is of paramount importance to enable the patients receiving home care and their relatives to adapt social life, to fulfil their social integration, to relieve the burden of family members of the individual in need of care, especially the individual providing care, by supporting them in the environment where they live. in this study, it is aimed to investigate the effect of the family support program based on the nurse-led case management model for family members who care for bedridden patients.the family support program based on a five-stage nurse-led case management model is administered for the caregivers in the intervention group, the caregivers in the control group is monitored by home health services through routine follow-ups. the research will conducted as a randomized controlled study with an experimental design.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the study, * to have been taking care of the caregiver for at least 6 months, * being literate * not to have sensory loss such as vision and hearing, * being open to communication and cooperation, * internet access and being able to use it, * having a phone where he can be reached, * not receiving any remuneration for the provision of care, * having a family bond with the person being cared for. exclusion criteria: * caregivers who do not meet the inclusion criteria, * caregivers who did not give consent at any stage of the study and left.

Keywords: caregiver case management nurse-led
operating room outcomes after resident training on a virtual reality simulator

Conditions: Gall Bladder Disease

Summary: the purpose of this study is to compare outcomes of patients undergoing laparoscopic cholecystectomy before and after a laparoscopic training curriculum was implemented.

all general surgery interns and pgy-2's and pgy 3's will be enrolled in a laparoscopic surgery training curriculum that includes practicing surgical skills on a laparoscopic simulator. the pi has constructed an examination on the simulator that will document a significant level of laparoscopic skill. each general surgery intern, second, and third year general surgery resident will be required to pass this examination on the simulator prior to being given more responsibility during cases of laparoscopic cholecystectomy. specifically, interns, second, and third year residents must pass the examination on the simulator before they are allowed to function as primary surgeon in a supervised setting during laparoscopic cholecystectomy. these interns, pgy-2's, and pgy 3's would then be allowed to function as primary surgeon under the supervision of an attending surgery for laparoscopic cholecystectomy cases. the outcomes of these cases would be compared to a matched group of laparoscopic cholecystectomy cases performed by second year general surgery residents in the same supervised environment (but without having trained on the simulator) one year prior.

Eligibility criteria:
inclusion criteria: * general surgery residents at newyork hospital/columbia in pgy 1, 2, or 3. exclusion criteria: * persons who are not general surgery residents at newyork hospital/columbia in pgy 1, 2, or 3.

Keywords: resident training laparoscopy virtual reality surgical education
the effect of pelvic floor exercise on urinary incontinence and quality of sex life

Conditions: Pelvic Floor Muscle Weakness; Urinary Incontinence

Summary: this physiotherapist-guided group training programme should be performed in both the supine and the sitting positions; it is investigated, which is better and more cost-effective in patient motivation.

here we aimed to investigate whether-based on trunk muscle synergism-the condition and functioning of the pelvic floor muscle would improve in the sitting and supine postures or in the control group during pelvic floor muscle training with forced exhalation. we enrolled nulliparous women in supine (n = 22), sitting (n = 19) and control (n = 14) groups. we performed the 8-week combined pelvic floor muscle training programme. we examined the effect of training on the parameters with the kruskal-wallis test, and the pairwise comparisons with the mann-whitney u-test and the wilcoxon-rank test with the bonferroni correction.

Eligibility criteria:
inclusion criteria: * we included in the study groups women participants willing to participate in the study and able to contract the pelvic floor and transversus abdominis muscles correctly. participants were required to maintain their everyday activities (attending lessons, sport activities, and so on). exclusion criteria: * known neurological or rheumatological diseases and previous vaginal or abdominal surgery.

Keywords: pelvic floor muscle training transverse abdominal muscle ultrasound measurement urinary incontinence vaginal surface electromyography
nepafenac versus ketorolac eye drops in prevention of intraoperative miosis during cataract surgery

Conditions: Cataract; Miosis

Summary: this study aim at determining the efficacy of nepafenac and ketorolac in obtaining adequate intraoperative mydriasis and preventing miosis during cataract surgery. it also compare the efficacy of both nepafenac versus ketorolac, and determine the more effective agent in preventing miosis during cataract surgery. the investigators try to determine if the effect of preoperative nsaids agents use would show a financial benefit, or this manoeuvre would add a financial load on the patients who are candidate for cataract surgery.

maintaining adequate mydriasis is one of the most important prerequisites during both extracapsular cataract extraction and phacoemulsification intervention. the importance of intraoperative maintenance of mydriasis arises from the necessity for the surgeon to insert intra-ocular lens in the posterior chamber of the eye. it is now well established that non-steroidal anti-inflammatory drugs (nsaids) reduce intraoperative miosis during cataract surgery. topical flurbiprofen, indomethacin and diclofenac with and without intraoperative epinephrine are the commonest topical non-steroidal eye drops with which nearly all publications in the literature studied the prevention of intraoperative surgery-induced miosis. in addition, diclofenac was found to be the most effective nsaids agent in maintaining intraoperative mydriasis. more recently, evidence that some nsaids, namely ketorolac and flurbiprofen, may have a role in preventing pseudophakic cystoid macular oedema. patients whom eyes are pre-treated with some nsaids, especially diclofenac, shows a statistically significant reduction in the degree of postoperative inflammation (e.g., redness, pain and itching) on the first post-operative day. on the contrary, thaller et al found, in his study at 2000, that no statistically significant difference in the postoperative redness, pain and cells in the anterior chamber. administration of adrenalin in the anterior chamber fluid is found by several studies to be more effective in maintaining intraoperative mydriasis than preoperative treatment with nsaids.

Eligibility criteria:
inclusion criteria: * patients with cataract who are candidate for cataract surgery exclusion criteria: * d.m, * patient with other ocular comorbidities rather than cataract, * patients with history of trauma. * patients on corticosteroid drops treatment. * previous intraocular surgery.

Keywords: cataract surgery intraoperative miosis ketorolac eye drops nepafenac eye drops
frequency of circulating tumour cells in stage ii and stage iii colon cancer patients

Conditions: Colon Cancer

Summary: this study will determine whether a new diagnostic test called the cell search assay can detect circulating colon cancer cells in patients who have had surgery for colon cancer and had visible cancer removed. other parts of the study will look at whether the presence of the circulating tumor cells in blood predicts whether a patient will have their colon cancer return.


Eligibility criteria:
inclusion criteria: * stage ii or iii colon cancer exclusion criteria: * none

Keywords: colon cancer
effect of mechanical circulatory support on exercise capacity among patients with heart failure

Conditions: Heart Failure，Congestive

Summary: this study will evaluate how the cardiovascular system interacts with mechanical hearts to provide blood flow to the body during exercise. two aims are proposed: 1) to determine the impact of a mechanical heart on exercise pressor reflexes in heart failure patients; and 2) to define the primary determinant(s) of exercise capacity in heart failure patients before and after device implantation.


Eligibility criteria:
advanced heart failure- inclusion criteria: * individuals with severely reduced left ventricular systolic function that are scheduled to undergo lvad insertion exclusion criteria: * uncontrolled diabetes with peripheral neuropathy (interferes with acquisition of msna signal) * individuals with clinical right ventricular failure, defined as moderate-severely reduced rv systolic function on echocardiography, or clinical evidence of rv failure (elevated jugular venous pressures, significant peripheral edema) * individuals with moderate-severe preexisting aortic insufficiency, as these patients will typically undergo a park stitch at time of cf-lvad insertion to permanently close the aortic valve and prevent worsening aortic insufficiency; and * disorders that adversely influence exercise ability (e.g. arthritis, peripheral vascular disease, pulmonary disease) mild heart failure - inclusion criteria: * individuals with medically managed left ventricular systolic function that are not scheduled to undergo lvad insertion * hf patients with ejection fraction \<35-40% exclusion criteria: * individuals requiring systemic anticoagulation with vitamin-k antagonists or new/direct oral anticoagulants ("noac"/"doac") * disorders that adversely influence exercise ability (e.g. arthritis, peripheral vascular disease, pulmonary disease) * history of uncontrolled arrhythmias (e.g. ventricular tachycardia or nonsustained ventricular tachycardia). healthy controls - inclusion criteria: - persons without a past medical history of cardiovascular disease or related disease (e.g. hypertension, diabetes, peripheral vascular disease, arrhythmias, stroke/transient ischemic attack) and are not taking any cardiac-related medications (e.g. antihypertensive medications) exclusion criteria: * individuals requiring systemic anticoagulation with vitamin-k antagonists or new/direct oral anticoagulants ("noac"/"doac") * disorders that adversely influence exercise ability (e.g. arthritis, peripheral ascular disease).
prasugrel re-load strategies

Conditions: Coronary Artery Disease

Summary: a higher degree of platelet inhibition remains the goal of peri-interventional and long-term anti-thrombotic therapy in patients with coronary artery disease. in clinical practice, patients undergoing percutaneous coronary intervention with stent implantation who are already on clopidogrel therapy get re-loaded with clopidogrel. this is based on prior observations showing that higher inhibition of platelet aggregation may be achieved by giving a loading dose of clopidogrel in patients with coronary artery disease while on chronic clopidogrel therapy. however, to date it is unknown if greater inhibition of platelet aggregation can be achieved by adding a prasugrel loading dose in patients on chronic prasugrel therapy. therefore, understanding the pharmacodynamic implications of a prasugrel re-load strategy in patients on already on chronic prasugrel therapy will be useful.


Eligibility criteria:
inclusion criteria: 1. patients with angiographically documented coronary artery disease. 2. age between 18 to 74 years 3. on treatment with prasugrel 10mg/daily for at least 14 days. exclusion criteria: 1. blood dyscrasias or bleeding diathesis 2. antiplatelet treatment with clopidogrel or ticlopidine 3. recent antiplatelet treatment (\< 14 days) with a glycoprotein iib/iiia antagonist 4. platelet count \<100x106/µl 5. active bleeding or hemodynamic instability. 6. unstable angina, acute or recent (\<14 days) myocardial infarction. 7. serum creatinine \>2 mg/dl 8. baseline alt \>2.5 times the upper limit of normal 9. oral anticoagulation with a coumarin derivative 10. history of stroke, tia or intracranial bleeding 11. weight \<60kg 12. pregnant females

Keywords: coronary artery disease percutaneous coronary revascularization prasugrel therapy
a prospective, multi-center, single-arm study of the veriset™ hemostatic patch in controlling bleeding in soft tissue

Conditions: Non-emergent, Soft Tissue Procedures, Performed Via an Open Approach

Summary: the objective of this study is to determine the safety of veriset™ hemostatic patch when used during non-emergent, open, soft tissue surgery where a topical hemostatic agent would be used.


Eligibility criteria:
inclusion criteria: * subject or authorized representative has provided informed consent. * subject is ≥ 18 years old. * subject is scheduled for nonemergent surgery where a topical hemostatic agent would be used to control bleeding emanating from a tissue bed following organ dissection or removal or a bleeding tumor tissue bed following resection or dissection, via an open approach. * subject is willing and able to comply with all aspects of the treatment and evaluation schedule. * subject has an appropriate target bleeding site (tbs) during the surgical procedure. * tbs bleeding assessment is type 2 or 3 (refer to table in protocol). exclusion criteria: * subject is pregnant (documented by a positive pregnancy test) or is actively breast-feeding. * subject has an estimated life expectancy of less than 6 months. * subject is scheduled for another planned surgery and the subsequent surgery would jeopardize the previous application of study treatment. * subject is undergoing emergency surgery, i.e. lifesaving procedures performed where patient is in imminent danger of death. * subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with the study. * subject has an active local infection at the tbs. * the investigator determines that participation in the study may jeopardize teh safety or welfare of the subject.
a study to evaluate the safety, reactogenicity and immunogenicity of gsk biologicals' staphylococcal investigational vaccine in healthy adults

Conditions: Infections, Staphylococcal

Summary: the purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of several formulations of an investigational staphylococcal vaccine.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes can and will comply with the requirements of the protocol. * a male or female between 18 and 40 years of age, inclusive, at the time of first vaccination. * written informed consent obtained from the subject. * healthy subjects as established by medical history, clinical examination and laboratory assessment before entering into the study. * female subjects of non-childbearing potential may be enrolled in the study. * female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test at screening, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series exclusion criteria: * use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period. * chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose. * any clinically significant acute or chronic, local or systemic infection, proven or suspected to be caused by staphylococcus aureus and requiring antibiotic treatment, within the 6 months preceding the first vaccination. * previous administration of any investigational staphylococcus aureus vaccine/antibodies. * history of; or current bleeding or coagulation disorder. * known or suspected reaction or hypersensitivity likely to be exacerbated by any component of the vaccines. * history of; or current autoimmune or other immune-mediated disease. * administration or planned administration, of any vaccine not foreseen by the study protocol within 30 days of the first dose of vaccines up to 1 month after the last vaccine dose. * administration of immunoglobulins and/or any blood products within the last 3 months preceding the first dose of study vaccine or planned administration during the study period. * any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection. * any clinically relevant abnormal haematological or biochemical or urine laboratory values at screening. * any acute or chronic, clinically significant disease, as determined by physical examination or laboratory screening tests. * acute disease and/or fever at study entry. * pregnant or lactating female. * female planning to become pregnant or planning to discontinue contraceptive precautions. * history of; or current alcoholism and/or drug abuse. * any other condition that the principal investigator judges may interfere with study findings.

Keywords: vaccine young adults staphylococcus aureus